See more : Aramex PJSC (ARMX.AE) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCyte Biotech, Inc. (PMCB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCyte Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Telo Genomics Corp. (TDSGF) Income Statement Analysis – Financial Results
- Hoosiers Holdings Co., Ltd. (3284.T) Income Statement Analysis – Financial Results
- Apollo Global Management, Inc. (APO) Income Statement Analysis – Financial Results
- Vivo Energy plc (VVO.L) Income Statement Analysis – Financial Results
- One More Level SA (1OJ.F) Income Statement Analysis – Financial Results
PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.16K | 66.56K | 126.00K | 262.93K | 653.13K | 1.19M | 1.17M | 537.04K | 86.37K | 2.38K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.62K | 19.38K | 32.10K | 228.66K | 427.41K | 266.20K | 171.01K | 0.00 | 41.40K | 780.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K | 47.18K | 93.89K | 34.27K | 225.72K | 923.75K | 998.65K | 537.04K | 44.97K | 1.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.89% | 70.88% | 74.52% | 13.03% | 34.56% | 77.63% | 85.38% | 100.00% | 52.07% | 67.27% | 0.00% | 0.00% |
| Research & Development | 407.43K | 468.54K | 690.94K | 916.25K | 301.22K | 460.05K | 2.00M | 1.18M | 1.41M | 3.48M | 323.50 | 0.00 | 0.00 | 9.21K | 492.46K | 473.51K | 412.88K | 133.84K | 119.01K | 1.11M | 1.41M | 0.00 | 0.00 |
| General & Administrative | 4.79M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 9.99M | 18.11M | 1.58M | 1.99M | 462.22K | 1.24M | 5.20M | 0.00 | 0.00 | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.50K | 872.20K | 106.41K | 11.15K | 10.83K | 411.72K | 594.34K | 0.00 | 0.00 | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.12M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 10.22M | 18.98M | 1.69M | 2.00M | 473.05K | 1.65M | 5.79M | 4.26M | 4.47M | 7.75M | 3.10M | 313.95K | 32.13K | 0.00 |
| Other Expenses | 0.00 | 202.00K | -4.28K | -1.19K | -40.00 | 33.40K | 152.59K | 2.52M | 10.54K | 3.34M | -5.90M | 2.59K | 1.22M | 103.90K | 0.00 | 4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.85K |
| Operating Expenses | 8.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.69M | 2.00M | 482.25K | 2.14M | 6.27M | 4.67M | 4.61M | 7.87M | 4.21M | 1.72M | 32.13K | 29.85K |
| Cost & Expenses | 6.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.70M | 2.02M | 514.36K | 2.37M | 6.70M | 4.94M | 4.78M | 7.87M | 4.25M | 1.72M | 32.13K | 29.85K |
| Interest Income | 3.40M | 1.94M | 157.65K | 3.05 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 0.00 | 0.00 | 0.00 | 0.00 | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 509.00 | 3.05K | 453.00 | 0.00 | 0.00 | 1.54K | 1.19K | 4.94K | 21.05K | 154.42K | 241.25K | 171.66K | 292.56K | 27.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 492.05K | -5.89M | 2.59K | 24.66K | 40.69K | 114.91K | 28.83K | 6.38K | 1.35K | 488.00 | 23.26K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -3.83M | 0.00 | 0.00 | -4.44M | 0.00 | -9.92M | -27.23M | -1.68M | -1.63M | -388.36K | -2.11M | -5.99M | -3.78M | -3.61M | -7.33M | -1.72M | -1.73M | -32.13K | -29.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,830.35% | -3,328.88% | 388.91% | 607.14% | -922.67% | -308.99% | -308.83% | -1,049.52% | -4,810.34% | -72,213.26% | 0.00% | 0.00% |
| Operating Income | -6.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M | -6.07M | -13.70M | -18.98M | -1.68M | -1.95M | -388.36K | -2.11M | -6.04M | -3.75M | -3.61M | -7.34M | -4.16M | -1.72M | -32.13K | -29.85K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,851.65% | -2,928.55% | -308.23% | -802.09% | -925.09% | -315.07% | -308.42% | -1,365.85% | -4,819.57% | -72,213.26% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 2.14M | 152.85K | 71.75K | -493.00 | 33.40K | 152.59K | -1.54K | 9.35K | 2.84M | -8.27M | 86.26K | 49.87K | -837.69K | -3.88M | 471.00 | -42.72K | -6.79K | -1.76M | -114.04K | 1.73M | 0.00 | 0.00 |
| Income Before Tax | 333.76K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.66M | -1.23M | -5.70M | -6.03M | -3.82M | -3.60M | -9.03M | -4.15M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,491.16% | -973.08% | -2,167.62% | -923.10% | -320.62% | -307.90% | -1,682.09% | -4,801.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -153.36K | 3.05K | 453.00 | -33.40K | -152.59K | -4.44K | -4.88K | 4.94K | 19.96K | 154.42K | -49.87K | 1.01M | 3.88M | -471.00 | 42.72K | 6.79K | 2.05M | 114.04K | 1.72M | 32.13K | 29.85K |
| Net Income | 333.76K | -4.32M | -4.09M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.90M | -1.40M | -5.99M | -6.04M | -3.79M | -3.61M | -9.39M | -4.28M | -1.72M | -32.13K | -29.85K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,853.62% | -1,109.32% | -2,278.89% | -925.02% | -318.66% | -309.00% | -1,747.61% | -4,951.60% | -72,375.79% | 0.00% | 0.00% |
| EPS | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| EPS Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| Weighted Avg Shares Out | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 645.76K | 563.54K | 501.60K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
| Weighted Avg Shares Out (Dil) | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 646.08K | 563.82K | 501.85K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will...
IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS
Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Without Addressing the Real Underlying Issues at the Company Questions the Company's Failure to Publicly Disclose...
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following letter to its shareholders in response to...
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following letter to its shareholders in response to...
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock.
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Board of Directors (Board) has authorized a...
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of studies to...
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of...
Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly...
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.
Source: https://incomestatements.info
Category: Stock Reports